Economic Evaluation of Dasatinib Compared To Nilotinib as Second Line Treatment of Chronic Myeloid Leukemia in Greece

Authors :: Georgia Kourlaba
G Vassilopoulos
Fotini Gialama
N. Maniadakis
G Gourzoulidis
F Diamantogiannis
Source :: Value in Health. 20:A443
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
Second line treatment
business.industry
Health Policy
Public Health, Environmental and Occupational Health
Myeloid leukemia
Dasatinib
Nilotinib
Internal medicine
Economic evaluation
Medicine
business
medicine.drug

Full Text Access

Tools